Is Baidu Stock a Sleeper AI Winner?
Although the recent policy decisions have gripped the market now,…
Sell
21
APYX Quote, Financials, Valuation and Earnings
Last price:
$0.99
Seasonality move
:
13.67%
Day range:
$0.93 - $1.00
52-week range:
$0.76 - $1.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.72x
P/B ratio:
2.59x
Volume:
93.3K
Avg. volume:
62.5K
1-year change:
-26.14%
Market cap:
$36.8M
Revenue:
$48.1M
EPS (TTM):
-$0.67
Analysts' Opinion
-
Consensus RatingApyx Medical has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.00, Apyx Medical has an estimated upside of 310.26% from its current price of $0.98.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $0.98.
Fair Value
-
According to the consensus of 3 analysts, Apyx Medical has 310.26% upside to fair value with a price target of $4.00 per share.
APYX vs. S&P 500
-
Over the past 5 trading days, Apyx Medical has overperformed the S&P 500 by 12.49% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Apyx Medical does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Apyx Medical revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Apyx Medical reported revenues of $14.2M.
Earnings Growth
-
Apyx Medical earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Apyx Medical reported earnings per share of -$0.12.
Enterprise value:
39.1M
EV / Invested capital:
--
Price / LTM sales:
0.72x
EV / EBIT:
--
EV / Revenue:
0.81x
PEG ratio (5yr expected):
-0.06x
EV / Free cash flow:
-2.08x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$29.4M
Return On Assets:
-34.41%
Net Income Margin (TTM):
-48.78%
Return On Equity:
-133.56%
Return On Invested Capital:
-45.86%
Operating Margin:
-21.43%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $44.5M | $52.3M | $48.1M | $14.7M | $14.2M | |
| Gross Profit | $29.1M | $33.8M | $29.4M | $8.9M | $9M | |
| Operating Income | -$23.6M | -$20M | -$18.8M | -$5.8M | -$3M | |
| EBITDA | -$22M | -$18.1M | -$16.8M | -$8.3M | -$2.8M | |
| Diluted EPS | -$0.67 | -$0.54 | -$0.67 | -$0.28 | -$0.12 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $66.1M | $60.7M | $43M | $70.4M | $56.4M | |
| Total Assets | $74.1M | $68.7M | $51.8M | $79.2M | $64.8M | |
| Current Liabilities | $9.2M | $13.2M | $11.9M | $12.7M | $10.7M | |
| Total Liabilities | $10.3M | $14.7M | $14M | $52.3M | $50.5M | |
| Total Equity | $63.9M | $54M | $37.8M | $26.9M | $14.3M | |
| Total Debt | -- | -- | -- | $33.2M | $33.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$20.3M | -$5.2M | -$18M | -$2.2M | -$2.9M | |
| Cash From Investing | -$1M | $6.7M | -$722K | -$93K | -$245K | |
| Cash From Financing | $217K | $32.2M | $6.7M | $23.8M | $6.8M | |
| Free Cash Flow | -$21.3M | -$5.8M | -$18.8M | -$2.3M | -$3.2M | |
APYX
Sector
Market Cap
$36.8M
$35M
Price % of 52-Week High
49%
42.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-26.14%
-41.61%
Beta (5-Year)
0.924
0.742
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.95
200-day SMA
Sell
Level
$1.33
Bollinger Bands (100)
Sell
Level
1.17 - 1.63
Chaikin Money Flow
Buy
Level
38.7M
20-day SMA
Sell
Level
$1.12
Relative Strength Index (RSI14)
Sell
Level
42.33
ADX Line
Sell
Level
17.36
Williams %R
Neutral
Level
-67.3457
50-day SMA
Sell
Level
$1.23
MACD (12, 26)
Sell
Level
-0.08
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
48.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.2704)
Sell
CA Score
(Annual)
Level (-2.2839)
Buy
Beneish M-Score
(Annual)
Level (-2.7117)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (3.9539)
Sell
Piotroski F Score
(Annual)
Level (2)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
Stock Forecast FAQ
In the current month, APYX has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The APYX average analyst price target in the past 3 months is $4.00.
-
Where Will Apyx Medical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Apyx Medical share price will rise to $4.00 per share over the next 12 months.
-
What Do Analysts Say About Apyx Medical?
Analysts are divided on their view about Apyx Medical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Apyx Medical is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Apyx Medical's Price Target?
The price target for Apyx Medical over the next 1-year time period is forecast to be $4.00 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is APYX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Apyx Medical is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of APYX?
You can purchase shares of Apyx Medical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Apyx Medical shares.
-
What Is The Apyx Medical Share Price Today?
Apyx Medical was last trading at $0.99 per share. This represents the most recent stock quote for Apyx Medical. Yesterday, Apyx Medical closed at $0.98 per share.
-
How To Buy Apyx Medical Stock Online?
In order to purchase Apyx Medical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
JPMorgan Is The Rally Over?
JPMorgan Chase (NYSE:JPM) share price is up 29% over the…
Is BlackRock a Buy, Sell or Hold
With a large suite of ETF offerings as well as…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 32x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
23
UNH alert for Apr 18
UnitedHealth Group [UNH] is down 22.4% over the past day.
Sell
32
MAN alert for Apr 18
ManpowerGroup [MAN] is down 19.07% over the past day.
Sell
24
GPN alert for Apr 18
Global Payments [GPN] is down 17.44% over the past day.
